Research Article
Comparison of Ticagrelor and Clopidogrel in Elective Coronary Stenting: A Double Blind Randomized Clinical Trial
Table 3
Baseline medications of patients in the clopidogrel and ticagrelor groups, n (%).
| | Clopidogrel | Ticagrelor | value | (n = 223) | (n = 214) |
| Statins | 219 (98.2%) | 210 (98.1%) | 1 | Beta-blockers | 154 (69.1%) | 132 (61.7%) | 0.109 | Diuretics | 29 (13%) | 22 (10.3%) | 0.456 | Calcium channel blockers | 47 (21.1%) | 41 (19.2%) | 0.635 | Angiotensin-converting enzyme inhibitors | 32 (14.3%) | 13 (6.1%) | 0.005 | Angiotensin II receptor blockers | 86 (38.6%) | 93 (43.5%) | 0.331 | Nitrates | 75 (33.6%) | 106 (49.5%) | 0.001 | Proton pump inhibitors | 78 (35%) | 85 (39.7%) | 0.323 |
|
|